ATC Group: M01AX01 Nabumetone

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M01AX01 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M01 Antiinflammatory and antirheumatic products
3 M01A Antiinflammatory and antirheumatic products, non-steroids
4 M01AX Other antiinflammatory and antirheumatic agents, non-steroids
5 M01AX01 Nabumetone

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 1 g

Active ingredients in M01AX01

Active Ingredient Description
Nabumetone

Nabumetone is a non acidic non steroidal anti-inflammatory agent with weak prostaglandin synthesis properties. Nabumetone undergoes rapid and extensive metabolism in the liver to 6-methoxy-2-naphthylacetic acid (6-MNA), the principal active metabolite which is a potent inhibitor of prostaglandin synthesis.

Related product monographs

Title Information Source Document Type  
RELAFEN Tablet FDA, National Drug Code (US) MPI, US: SPL/Old

Medicines in this ATC group

United States (US)

Estonia (EE)

France (FR)

Germany (DE)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Netherlands (NL)

Poland (PL)

South Africa (ZA)

Spain (ES)

Turkey (TR)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.